FDA Brief

Warning letters Drugs

FDA warning letter to

Fagron BV

High riskIssued May 12Posted Jun 9Center for Drug Evaluation and Research (CDER)

FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

What happened

FDA inspected the Canton, Massachusetts site from October 9 to November 5, 2025; the site is registered as an outsourcing facility, a compounder that makes sterile drugs in advance rather than for one named patient. Investigators saw operators' arms blocking sterile first air to vancomycin vials, vials shaken hard enough to disrupt unidirectional airflow, smoke studies that did not reflect real production conditions, and gaps in cleaning, environmental monitoring and investigation of leaking IV bags. The firm recalled various lots of drugs made with certain IV bags on February 5, 2026 because sterility could not be assured.

What FDA found

  1. Sterile drugs were handled in conditions that could contaminate them: operators' arms blocked the first air reaching sterile vials, vials were shaken vigorously, and smoke studies did not show airflow under real production conditions.

    FDCA section 501(a)(2)(A)
  2. The quality unit did not make sure drug products met their established specifications for identity, strength, quality and purity.

    21 CFR 211.22
  3. The firm did not thoroughly investigate unexplained discrepancies or batch failures, and kept using IV bags with a known port-defect trend without a root cause or a pause in production.

    21 CFR 211.192
  4. The firm lacked adequate written procedures, including validation, to prevent microbiological contamination of products meant to be sterile.

    21 CFR 211.113(b)
  5. Air monitoring in the aseptic areas was inadequate, and the written procedure for placing settle plates did not cover the ISO 5 work area.

    21 CFR 211.42(c)(10)(iv)
  6. Cleaning and disinfection of aseptic rooms was inadequate (rust-like residue on hood wheelbases) and the buildings were not kept in good repair (chipped paint, a divot in the floor).

    21 CFR 211.42(c)(10)(v); 21 CFR 211.58

What FDA wants

FDA asks the company to write back within 15 working days with the specific steps taken to fix each violation, how recurrence will be prevented, and supporting documentation, or an explanation of why more time is needed. FDA also strongly recommends a full assessment of the aseptic operations with help from a third-party consultant who has sterile drug manufacturing expertise.

Who should pay attention

  • hospitals, clinics and pharmacies that buy compounded sterile drugs from outsourcing facilities
  • companies buying or distributing IV fluid bags and sterile compounds made at this site
  • other 503B outsourcing facilities with similar aseptic filling and airflow controls

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk
  4. Apothecary Pharma, LLC

    FDA warns Apothecary Pharma, an outsourcing facility, that its sterile compounded drugs were made under insanitary conditions.

    High risk